BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17589944)

  • 1. Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer.
    Vento P; Mustonen H; Joensuu T; Kärkkäinen P; Kivilaakso E; Kiviluoto T
    World J Gastroenterol; 2007 Jun; 13(21):2945-51. PubMed ID: 17589944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
    Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
    Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of a patient with borderline resectable pancreatic cancer. Case report and review.
    Shah AP; Strauss JB; Leslie WT; Shah A; Mahon B; Abrams RA
    Oncology (Williston Park); 2008 Nov; 22(13):1524-9. PubMed ID: 19133606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.
    Yeo CJ; Abrams RA; Grochow LB; Sohn TA; Ord SE; Hruban RH; Zahurak ML; Dooley WC; Coleman J; Sauter PK; Pitt HA; Lillemoe KD; Cameron JL
    Ann Surg; 1997 May; 225(5):621-33; discussion 633-6. PubMed ID: 9193189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
    JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
    Pisters PW; Hudec WA; Lee JE; Raijman I; Lahoti S; Janjan NA; Rich TA; Crane CH; Lenzi R; Wolff RA; Abbruzzese JL; Evans DB
    J Clin Oncol; 2000 Feb; 18(4):860-7. PubMed ID: 10673529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemoradiation for pancreatic adenocarcinoma].
    Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?].
    Lluís F
    Gastroenterol Hepatol; 2009 Feb; 32(2):120-1. PubMed ID: 19231687
    [No Abstract]   [Full Text] [Related]  

  • 9. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
    Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
    Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
    Pisters PW; Abbruzzese JL; Janjan NA; Cleary KR; Charnsangavej C; Goswitz MS; Rich TA; Raijman I; Wolff RA; Lenzi R; Lee JE; Evans DB
    J Clin Oncol; 1998 Dec; 16(12):3843-50. PubMed ID: 9850029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
    Hsu CC; Herman JM; Corsini MM; Winter JM; Callister MD; Haddock MG; Cameron JL; Pawlik TM; Schulick RD; Wolfgang CL; Laheru DA; Farnell MB; Swartz MJ; Gunderson LL; Miller RC
    Ann Surg Oncol; 2010 Apr; 17(4):981-90. PubMed ID: 20087786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
    Kachnic LA; Shaw JE; Manning MA; Lauve AD; Neifeld JP
    Int J Cancer; 2001 Apr; 96(2):132-9. PubMed ID: 11291097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):454-9. PubMed ID: 15145162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer.
    Epelbaum R; Rosenblatt E; Nasrallah S; Faraggi D; Gaitini D; Mizrahi S; Kuten A
    J Surg Oncol; 2002 Nov; 81(3):138-43. PubMed ID: 12407726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent chemoradiotherapy for advanced pancreatic cancer: 1,000 mg/m2 gemcitabine can be administered using limited-field radiotherapy.
    Yamazaki H; Nishiyama K; Koizumi M; Tanaka E; Ioka T; Uehara H; Iishi H; Nakaizumi A; Ohigashi H; Ishikawa O
    Strahlenther Onkol; 2007 Jun; 183(6):301-6. PubMed ID: 17520183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.